Insight Molecular Diagnostics eyes $2B market opportunity. The NASDAQ-listed company announced FDA submission of GraftAssureDx, positioning itself as the first dd-cfDNA assay under regulatory review. CEO Joshua Riggs signaled an aggressive commercialization strategy, highlighting the diagnostic's potential in transplant monitoring. The market opportunity reflects growing demand for non-invasive graft rejection detection. FDA authorization could unlock significant revenue streams and establish IMDX as a leader in molecular diagnostics. Investors are watching for regulatory milestones that could validate the company's commercial projections and drive adoption across transplant centers nationwide.
Post from MarketNews_en
Log in to interact with content.